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Abstract 
OBJECTIVE: To examine the effect of referral management on diabetes care. 
STUDY DESIGN: Cross-sectional analysis. 
PATIENTS AND METHODS: Translating Research Into Action for Diabetes (TRIAD) is a 
multicenter study of managed care enrollees with diabetes. Prospective referral management was 
defined as "gatekeeping" and mandatory preauthorization from a utilization management office, 
and retrospective referral management as referral profiling and appropriateness reviews. 
Outcomes included dilated eye exam; self-reported visit to specialists; and perception of 
difficulty in getting referrals. Hierarchical models adjusted for clustering and patient age, gender, 
race, ethnicity, type and duration of diabetes treatment, education, income, health status, and 
comorbidity. 
RESULTS: Referral management was commonly used by health plans (55%) and provider 
groups (52%). In adjusted analyses, we found no association between any referral management 
strategies and any of the outcome measures. 
CONCLUSIONS: Referral management does not appear to have an impact on referrals or 
perception of referrals related to diabetes care. 
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Referral management and the care of patients with diabetes: the Translating Research Into 
Action for Diabetes (TRIAD) study 
During the 1980s, referral management was introduced into managed care to reduce unnecessary 
services and contain healthcare costs.1,2 These strategies may be prospective (eg, "gatekeeping," 
mandatory preauthorization from a utilization management office) or retrospective (eg, profiling 
of referral patterns, retrospective review of appropriateness). Referral management has been 
unpopular among patients and physicians.3-6 In some,7-9 but not all,10,11 settings, it may have led 
to decreased use of specialists. 
The effect of referral management on diabetes care remains unclear. Persons with diabetes, like 
persons with other chronic diseases, use more healthcare services and have greater healthcare 
expenditures than patients without chronic diseases.12,13 As a result, patients with chronic 
diseases may be particularly sensitive to strategies designed to decrease use of unnecessary 
services.14,15 However, the effects of referral management strategies other than gatekeeping, 
including practice profiling, have been relatively understudied. To our knowledge, only 1 study 
has examined referral management in cases of diabetes, and that study could not assess diabetes 
processes of care.16 
The Translating Research Into Action for Diabetes (TRIAD) study is a multicenter, prospective 
cohort study designed to examine how managed care structure influences the processes and 
outcomes of diabetes care.17 Using TRIAD, we examined the association between individual and 
multiple referral management strategies and specialist use and patient dissatisfaction with 
diabetes care. We hypothesized that during the previous year, greater use of referral management 
strategies would be associated with 1) a lower probability of study participants receiving a 
dilated eye exam, 2) fewer self-reported visits to specialists, 3) increased perception of difficulty 
in getting specialist referrals, and 4) greater dissatisfaction with the quality of diabetes care. We 
examined these 4 outcomes because they represent 4 possible mechanisms of action of referral 
management strategies. We also hypothesized that the associations would be stronger with 
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prospective referral management strategies than with retrospective referral management 
strategies. 
METHODS 
Study Setting 
TRIAD has been previously described.17 The underlying hypothesis of TRIAD is that structural 
and organizational characteristics of health systems and provider groups affect processes of care, 
which, in turn, influence health and economic outcomes. Six Translational Research Centers 
collaborate with 10 health plans and 68 provider groups, which serve approximately 180 000 
patients with diabetes; centers are available on the web: www.trialstudy.org. Managed care 
health plans are defined as entities that deliver, administer, or assume risk for health services in 
order to influence the quality, access, cost, and outcomes of healthcare for a defined population. 
Provider groups include groups of physicians with contractual arrangements with 1 or more 
health plans that provide managed care services. 18 The groups often are engaged directly in 
diabetes care management and may determine compensation arrangements and financial 
incentives for physicians and specialty referral policies. 
Study Population and Data 
For the purposes of this analysis, we examined health plans (n = 7) and provider groups (n = 51) 
that answered questions regarding referral management strategies and their participants with 
medical record information (a total of 6941 participants). Participants from 1 site (located in 
New Jersey and Pennsylvania) were excluded from this analysis due to lack of information on 
referral management strategies used by provider groups. Study participants were 18 years of age 
or older, community dwelling, English or Spanish speaking, continuously enrolled in the health 
plan for at least 18 months, and not pregnant; and they had at least 1 claim for health services 
during the previous 18 months. Participants were sampled from provider groups that had at least 
50 participants with diabetes enrolled in the study’s health plans. Recruitment was completed in 
September 2001. Institutional Review Board approval was obtained from each participating 
institution. 
Participant data were obtained from a survey that was administered either by computer-assisted 
telephone interview or in writing, and from a review of medical records. Of contacted eligible 
individuals, 91% responded to the survey. If individuals who could not be contacted had the 
same rate of eligibility as those who were contacted, and if they were counted in the 
denominator, the survey response rate would be 69% (this is commonly called the Council of 
American Survey Research Organizations (CASRO) response rate19). Survey questions assessed 
sociodemographic characteristics, diabetes- related service use, and general health status and 
quality-of-life measures,20,21 among other variables. Health plan and provider group data were 
assessed by using standardized interviews of health plan and provider group medical directors 
and leadership personnel. Interviews determined the presence of referral management strategies 
and other structural variables. 
Outcome Measures 
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Outcome measures were obtained from participant surveys. They were the receipt of a dilated 
eye exam, perception of difficulty in getting specialist referrals, any specialist visit, and 
participant dissatisfaction with the quality of diabetes care over the previous year. Each of the 
outcome measures was examined as a dichotomous measure. The last 2 outcome measures were 
adapted from questions from the Consumer Assessment of Health Plans Study 2.0 (CAHPS® 
2.0) survey.22 We chose to score perception of difficulty in getting referrals independently from 
CAHPS® 2.0 because of response patterns in TRIAD. (See Appendix for a detailed explanation 
of scoring and the TRIAD patient survey questions.) In the participant survey, specialists were 
defined as doctors that patients may have seen for special health needs, like surgeons, 
cardiologists, allergists, dermatologists, and others who specialize in a single area of healthcare. 
Dentists were specifically excluded. 
Referral Management 
-   
Health plan and provider group medical directors were asked whether referral management 
strategies were used by their organizations. Prospective referral management was defined as 
preapproval from primary care physicians for specialist referrals (gatekeeping) or mandatory 
preauthorization from a utilization management office for a referral to a specialist; these 
occurred before the referral had taken place. Retrospective referral management was defined as 
practice profiling of primary care physician referral patterns and retrospective review of referral 
appropriateness. We examined each of these strategies in unadjusted frequencies and then 
created 2 variables: the number of prospective strategies and the number of retrospective 
strategies, which both ranged from 0 (no strategies) to 2 strategies. Next, we examined the 
association between the number of prospective strategies and the outcome measures; then, the 
association between the number of retrospective strategies and the outcome measures. 
In a separate analysis, we accounted for the total number of strategies by creating an "intensity of 
referral management" variable, the unweighted sum of all of the referral management strategies 
both as a continuous and a categorical variable. When we examined the strategies as a 
continuous variable, we examined the impact of the total number of strategies; when we 
examined the strategies as a categorical variable, we looked for the presence of a threshold 
number of strategies that would affect our outcome measures. A participant could be exposed to 
a maximum of 4 strategies used by the health plan and 4 strategies used by the provider group, 
and the models accounted for the simultaneous effect of referral management strategies at the 
health plan and the provider group levels. 
Statistical Analysis 
We used hierarchical logistic regression models (SAS GLIMMIX Macro with penalized quasi-
likelihood estimation method [SAS, Cary, NC]) with random intercepts for health plan and 
provider group to account for the clustered study design (health plan, provider group, and 
participant levels) and dependency of participant characteristics within health plans and provider 
groups. To ensure that simultaneous modeling of referral management strategies at the health 
plan and provider group level did not diminish the effect of these strategies, we also created 
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models that examined referral management at the level of the health plan without controlling for 
referral management strategies at the provider group level, but found no difference. 
In adjusted models, we also included patient age, sex, race and ethnicity, education, income, 
diabetes duration and treatment, and self-reported health status. Because of concerns that we 
were overadjusting by including health status in the model, we also constructed an adjusted 
model that did not include self-reported health status. It produced little change in the results. In a 
sensitivity analysis, we used the Charlson index to adjust for medical comorbidity,23 but found 
little change in the results. Using the method described by Smith and Bates,24 we conducted a 
confidence limits analysis to determine a limit on the likely magnitude of any actual effect in 
outcomes between groups with and without referral management strategies. Such an analysis can 
be used instead of a post-hoc power calculation. 
RESULTS 
Characteristics of participants in this substudy of the TRIAD population are listed in Table 1. 
The mean age of the participants was 61 years, and 54% were women. The population was 
diverse. The majority of participants were treated with oral antidiabetic medications, insulin 
monotherapy, or insulin in combination with oral antidiabetic therapy; fewer than 10% 
controlled their diabetes with diet and exercise alone. More than three fourths of participants 
(78%) had a dilated eye exam in the past year, and more than half (57%) saw a specialist in the 
past 12 months. Of the patients who needed to see a specialist, only 6% reported a perception of 
any problem getting a referral to a specialist; and in these cases, the problem was perceived as 
small rather than big. Dissatisfaction with diabetes care was low, with fewer than 2% of 
participants rating care as "poor." 
The prevalence of specific referral management strategies is shown Table 2. At the level of the 
health plan, the largest number of participants were exposed to gatekeeping, followed by practice 
profiling and retrospective review of referrals. At the level of the provider group, the largest 
number of participants also were exposed to gatekeeping, followed by retrospective review of 
referrals, preauthorization from a utilization management office, and practice profiling. 
Approximately 55% of participants were affected by at least 1 health plan strategy, and 52% of 
participants were affected by at least 1 provider group strategy. 
Table 3 shows the association between referral management strategies and outcome measures. It 
compares outcome rates between groups and plans with referral management strategies and 
between groups and plans without such strategies after adjustment for patient covariates. The 
probability of an outcome is expressed along with differences in probabilities ("risk 
differences"). For example, patients in health plans with 1 prospective referral management 
strategy had a 63% probability of seeing a specialist over a year; patients in health plans with no 
prospective referral management strategies had a 61% probability of seeing a specialist over a 
year. A risk difference of "2" between a health plan with 1 prospective strategy and a health plan 
with no prospective strategy means that the patient’s probability of the outcome (eg, seeing a 
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specialist over a 1-year period) is 2 percentage points higher in health plans with no prospective 
strategies. 
Neither prospective nor retrospective referral management strategies were significantly 
associated with performance of a dilated eye exam over the past year, a visit to a specialist, or 
perceived difficulty in getting referrals (Table 3). Because of the high percentage of satisfied 
participants and the lack of variation in response, unadjusted models with patient dissatisfaction 
as a dependent variable did not converge, or could not yield estimates of effect. There were no 
differences between models unadjusted and adjusted for patient covariates. (See Table 4 for risk 
differences unadjusted for patient covariates.) When we looked at the number of strategies or the 
intensity of referral management, neither the linear nor the categorical variable was associated 
with any outcome measures (results not shown). 
We realized our small sample size gave us limited ability to detect a difference in outcomes 
between organizations with and without referral management strategies. Therefore, we calculated 
the likelihood that the difference between plans with and without referral management strategies 
and between groups with and without referral management strategies was greater than 10 
percentage points for each outcome measure.24 Our goal was to see whether we could have 
missed large differences between organizations with and without referral management strategies. 
Given the standard deviations and risk differences, the likelihood that groups with no prospective 
referral strategies would perform dilated eye examinations 10 percentage points more often than 
plans with such strategies was 11.5%, for rates of specialist referral was 0.2%, and for problems 
with difficulty of referral to specialists was 0.3%. In other words, the probability that outcomes 
differed by more than 10 percentage points between groups with and without referral 
management strategies was fairly low. Similar results were seen when plans with no 
retrospective referral strategies were compared 1) with plans that had retrospective referral 
strategies and 2) with plans that had both retrospective and prospective referral strategies. The 
exception was the association between rates of specialty referral and health plans strategies, 
where the possibility that the difference between health plans with and without referral strategies 
exceeded 10 percentage points was more than 12%. 
DISCUSSION 
We found no relationship between prospective and retrospective referral management strategies 
and performance of dilated eye exam, self-reported specialist use, or perception of difficulty in 
seeing a specialist in patients with diabetes across different models of managed care. These 
results extend more recent reports that show little, if any, effect of gatekeeping on specialist 
use.16,25 These results are reassuring in that others have speculated that referral management 
strategies may negatively affect access to needed services for persons with chronic illness.26,27 
Our results may reflect a trend toward more relaxed practices of gatekeeping, preauthorization, 
profiling, and retrospective review of referrals. Institution of referral management strategies at 
the provider group level usually occurs in response to health plan strategies, but actual denial of 
claims at the provider group level is uncommon.28 The lack of association between referral 
management strategies and perception of difficulty in getting a referral also could reflect the 
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diffusion of referral management strategies into managed care and their acceptance by patients. 
Finally, our results could reflect the presence of other diabetes management strategies such as 
disease management programs that did not necessarily hinge on the involvement of a specialist, 
and that would reduce both the perception of need and actual need for a specialty referral. 
Our analysis has several limitations. We examined a select group of health plans and provider 
groups with an interest in the quality of diabetes care, and these results do not necessarily extend 
to other managed care plans. The lack of more significant differences in diabetes processes of 
care by presence or number of referral management strategies may have been due to inadequate 
power. We did not examine how diabetes care management strategies modified the relationship 
between referral management strategies and our outcomes of choice, as we had limited power 
and this question was beyond the scope of our paper. However, further investigation on how 
other health systems’ interventions interact with referral management strategies could provide 
insight into the reasons why referral management appears to have little association with specific 
outcomes. 
This analysis is cross-sectional, and we did not examine how long referral management strategies 
had been in place. It is possible that immediately after implementation, such strategies reduced 
service use or were perceived more negatively, but the effect waned over time. Although 
accepted by diabetes quality organizations,29 these measures have limitations in that they may 
not capture management strategies30 and may not necessarily be appropriate for all persons with 
diabetes; for example, performance of annual dilated eye exams in participants with excellent 
glycosolated hemoglobin measures may not represent optimal resource use.31 We did not analyze 
actual utilization and cost associated with referral management strategies, and it is possible that 
these strategies would have some effect on these end points. Finally, it is possible that that these 
mechanisms, gatekeeping in particular, may serve other functions such as to integrate care,32 but 
we did not assess this function. 
CONCLUSION 
Referral management strategies have little effect on rates of dilated eye exams, perception of 
difficulty in getting referral to specialists, or specialist referral in a population with chronic 
disease. 
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